

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **ANNOUNCEMENT**

### **UNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAO FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024**

On 30 October 2024, Dong-E-E-Jiao released its quarterly report for the nine months ended 30 September 2024.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 30 October 2024, Dong-E-E-Jiao released its quarterly report for the nine months ended 30 September 2024 (the “**Dong-E-E-Jiao Unaudited Financials**”). Set out below is the key financial information of the Dong-E-E-Jiao Unaudited Financials:

	<b>For the nine months ended</b>	
	<b>30 September</b>	
	<b>2024</b>	2023
	<b>(RMB)</b>	<b>(RMB)</b>
	<b>(unaudited)</b>	<b>(unaudited)</b>
Revenue	<b>4,329,229,198.62</b>	3,428,282,500.66
Net profit	<b>1,152,145,315.53</b>	785,141,572.25
Net (decrease)/increase in cash and cash equivalents	<b>(1,519,048,999.29)</b>	713,835,351.41
Cash and cash equivalents at the end of the period	<b>4,278,097,432.77</b>	6,054,670,039.74
	<b>As of</b>	As of
	<b>30 September</b>	31 December
	<b>2024</b>	2023
	<b>(RMB)</b>	<b>(RMB)</b>
	<b>(unaudited)</b>	<b>(audited)</b>
Total assets	<b>12,715,273,642.98</b>	13,306,306,533.41
Total liabilities	<b>2,781,693,939.85</b>	2,565,744,617.42
Owner’s equity	<b>9,933,579,703.13</b>	10,740,561,915.99

The Dong-E-E-Jiao Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. The financial information is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Dong-E-E-Jiao Unaudited Financials, please refer to the quarterly report for the nine months ended 30 September 2024 published by Dong-E-E-Jiao on the website of the Shenzhen Stock Exchange ([www.szse.cn](http://www.szse.cn)).

By order of the Board of Directors  
**China Resources Pharmaceutical Group Limited**  
**Bai Xiaosong**  
*Chairman*

PRC, 30 October 2024

*As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Tao Ran and Mdm. Deng Rong as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors; and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*